Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

In vivo demonstration of Pseudomonas aeruginosa biofilms as independent pharmacological microcompartments

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Lung clearance index-triggered intervention in children with cystic fibrosis - A randomised pilot study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pseudomonas aeruginosa antibody response in cystic fibrosis decreases rapidly following lung transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The impact of chest computed tomography and chest radiography on clinical management of cystic fibrosis lung disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Severity of anaemia and association with all-cause mortality in patients with medically managed left-sided endocarditis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. Potential Advances of Adjunctive Hyperbaric Oxygen Therapy in Infective Endocarditis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

BACKGROUND: Pseudomonas aeruginosa is difficult to eradicate from the lungs of cystic fibrosis (CF) patients due to biofilm formation. Organs and blood are independent pharmacokinetic (PK) compartments. Previously, we showed in vitro biofilms behave as independent compartments impacting the pharmacodynamics. The present study investigated this phenomenon in vivo.

METHODS: Seaweed alginate beads with P. aeruginosa resembling biofilms, either freshly produced (D0) or incubated for 5 days (D5) were installed s.c in BALB/c mice. Mice (n = 64) received tobramycin 40 mg/kg s.c. and were sacrificed at 0.5, 3, 6, 8, 16 or 24 h after treatment. Untreated controls (n = 14) were sacrificed, correspondingly. Tobramycin concentrations were determined in serum, muscle tissue, lung tissue and beads. Quantitative bacteriology was determined.

RESULTS: The tobramycin peak concentrations in serum was 58.3 (±9.2) mg/L, in lungs 7.1 mg/L (±2.3), muscle tissue 2.8 mg/L (±0.5) all after 0.5 h and in D0 beads 19.8 mg/L (±3.5) and in D5 beads 24.8 mg/L (±4.1) (both 3 h). A 1-log killing of P. aeruginosa in beads was obtained at 8h, after which the bacterial level remained stable at 16 h and even increased in D0 beads at 24 h. Using the established diffusion retardation model the free tobramycin concentration inside the beads showed a delayed buildup of 3 h but remained lower than the MIC throughout the 24 h.

CONCLUSIONS: The present in vivo study based on tobramycin exposure supports that biofilms behave as independent pharmacological microcompartments. The study indicates, reducing the biofilm matrix would increase free tobramycin concentrations and improve therapeutic effects.

TidsskriftJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Udgave nummer6
Sider (fra-til)996-1003
Antal sider8
StatusUdgivet - nov. 2020

Bibliografisk note

Copyright © 2020. Published by Elsevier B.V.

ID: 61992860